• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Pizensy (lactitol)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Pizensy (lactitol)

  • Profile

Profile

Contact Information

Contact: Braintree Labs
Website: https://sebelapharma.com/prescribing-information/pizensy-pi.pdf

Currently Enrolling Trials

    Show More

    General Information

    Pizensy (lactitol) is an osmotic laxative. 

    Pizensy is specifically indicated for the treatment of chronic idiopathic constipation in adults.

    Pizensy is supplied as an off-white crystalline powder for oral solution. The recommended daily dosage is 20 grams (mixed with 4 to 8 ounces of water, juice, coffee, tea, or soda), preferably with meals. The dosage should be reduced to 10 grams daily in patients who have persistent loose stools.

    Mechanism of Action

    Pizensy (lactitol) exerts an osmotic effect, causing the influx of water into the small intestine leading to a laxative effect in the colon.

    Side Effects

    Adverse effects associated with the use of Pizensy may include, but are not limited to, the following:

    • upper respiratory tract infections
    • flatulence
    • diarrhea
    • increased blood creatinine phosphokinase
    • abdominal distension
    • increased blood pressure

    Clinical Trial Results

    The FDA approval of Pizensy was based on a 6-month placebo-controlled trial, a 3-month active-controlled trial, and a 1-year uncontrolled safety study. The primary efficacy analysis was based on the first 12 weeks of the 6-month treatment period among 594 patients, with 291 in the lactitol arm and 303 in the placebo arm. Significantly more patients using lactitol responded to treatment compared with placebo (25% vs 13%). A responder was defined as those patients who had at least three complete spontaneous bowel movements (CSBM) in a given week and an increase of at least one CSBM from baseline in the same week for at least 9 weeks out of the first 12-week treatment period and at least 3 of the last 4 weeks.

    Approval Date: 2020-02-01
    Company Name: Braintree Laboratories
    Back to Listings

    Upcoming Events

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing